[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20060264482A1 - Epothilones C, D, E and F, preparation and compositions - Google Patents

Epothilones C, D, E and F, preparation and compositions Download PDF

Info

Publication number
US20060264482A1
US20060264482A1 US11/412,536 US41253606A US2006264482A1 US 20060264482 A1 US20060264482 A1 US 20060264482A1 US 41253606 A US41253606 A US 41253606A US 2006264482 A1 US2006264482 A1 US 2006264482A1
Authority
US
United States
Prior art keywords
epothilone
methanol
epothilones
culture
biotransformation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/412,536
Inventor
Gerhard Hoefle
Heinrich Steinmetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060264482(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/412,536 priority Critical patent/US20060264482A1/en
Publication of US20060264482A1 publication Critical patent/US20060264482A1/en
Priority to US12/110,781 priority patent/US20080293784A1/en
Priority to US12/434,078 priority patent/US7759375B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Definitions

  • the present invention relates to epothilones C, D, E and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.
  • the invention relates to epothilones [C and D] which are obtainable in that
  • the invention further relates to an epothilone [C] of the empirical formula C 26 H 39 NO 5 S, characterized by the 1 H- and 13 C-NMR spectrum as in Table 1.
  • the invention furthermore relates to epothilone C of the formula:
  • the invention furthermore relates to epothilone [D] of the empirical formula C 27 H 41 NO 5 S, characterized by the 1 H- and 13 C-NMR spectrum as in Table 1.
  • the invention furthermore relates to epothilone D of the formula:
  • Epothilones C and D can be used for the preparation of the compounds of the following formula 1, where for their derivatization reference can be made to the derivatization methods described in WO-A-97/19 086.
  • formula 1 :
  • epoxidized for example with dimethyldioxirane or a peracid, a compound of the formula 1 being obtained with Y and Z ⁇ —O—; or
  • the invention relates to a biotransformant of epothilone A, which is obtainable in that
  • the invention furthermore relates to a biotransformant of epothilone A of this type, which is obtainable in that in stage (a) a culture is separated off which is three or four or more days old.
  • the invention furthermore relates to a biotransformant of epothilone A of this type, which is obtainable in that in stage (b) incubation is carried out for one or two or more days.
  • the invention furthermore relates to a compound (epothilone E) of the formula:
  • the invention relates to a biotransformant of epothilone B, which is obtainable in that
  • the invention furthermore relates to a biotransformant of epothilone B of this type, which is obtainable in that in stage (a) a culture is separated off which is three or four or more days old.
  • the invention furthermore relates to a biotransformant of epothilone B of this type, which is obtainable in that in stage (b) incubation is carried out for one or two or more days.
  • the invention furthermore relates to a compound (epothilone F) of the formula:
  • FIG. 1 shows a HPLC analysis of an XAD eluate at the end of a fermentation.
  • FIG. 2 shows an enrichment of epothilone E and F in a fermentation broth after feeding of a mixture of epothilone A and B, analysed after incubation for 48 hours.
  • FIG. 3 shows kinetics of the biotransformation of epothilone A to epothilone E by Sorangium cellulosum So ce90.
  • FIG. 4 shows biotransformation of epothilone A to epothilone E.
  • FIG. 5 shows biotransformation of epothilone B to epothilone F.
  • the compounds or epothilones according to the invention are obtainable by the abovementioned measures.
  • the invention furthermore relates to compositions for plant protection in agriculture, forestry and/or horticulture, consisting of one or more of the abovementioned epothilones C, D, E and F or consisting of one or more of the abovementioned epothilones in addition to one or more customary carrier(s) and/or diluent(s).
  • the invention finally relates to therapeutic compositions, consisting of one or more of the abovementioned compounds or one or more of the abovementioned compounds in addition to one or more customary carrier(s) and/or diluent(s).
  • these compositions can show cytotoxic activities and/or bring about immunosuppression and/or be employed for the control of malignant tumours, it being particularly preferably possible for them to be used as cytostatics.
  • the fermentation lasts 7-10 days at 30 C, aeration with 2 m 3 /hr. By controlling the speed of rotation, the pO 2 is kept at 30%.
  • the adsorber resin is separated from the culture using a 0.7 m 2 , 100 mesh process filter and freed from polar concomitants by washing with 3 bed volumes of water/methanol 2:1. By elution with 4 bed volumes of methanol, a crude extract is obtained which is evaporated in vacuo until the water phase appears. This is extracted three times with the same volume of ethyl acetate. Evaporation of the organic phase affords 240 g of crude extract, which is partitioned between methanol and heptane in order to separate off lipophilic concomitants.
  • epothilone A 50 mg are dissolved in 1.5 ml of acetone and treated with 1.5 ml of a 0.07 molar solution of dimethyldioxirane in acetone. After standing at room temperature for 6 hours, the mixture is evaporated in vacuo and the residue is separated by preparative HPLC on silica gel (eluent: methyl tert-butyl ether/petroleum ether/methanol 33:66:1).
  • Epothilone E and F Novel Biotransformation Products of Epothilones A and B
  • a typical fermentation proceeds in the following manner: A 100 l bioreactor is filled with 60 l of medium (0.8% starch; 0.2% glucose; 0.2% soya flour; 0.2% yeast extract; 0.1% CaCl 2 ⁇ 2H 2 O; 0.1% MgSO 4 ⁇ 7H 2 O; 8 mg/l of Fe-EDTA; pH 7.4). 2% of adsorber resin (XAD-16, Rohm & Haas) are additionally added. The medium is sterilized by autoclaving (2 hours, 120° C.). Inoculation is carried out with 10 l of a preculture grown in the same medium (additionally 50 mM HEPES buffer pH 7.4) in a shaker flask (160 rpm, 30° C.).
  • Fermentation is carried out at 32° C. with a stirrer speed of 500 rpm and an introduction of 0.2 N1 per m 3 per hour of air, the pH is kept at 7.4 by addition of KOH.
  • the fermentation lasts 7 to 10 days.
  • the epothilones formed are continuously bound to the adsorber resin during the fermentation.
  • the resin is washed with 3 bed volumes of water and eluted with 4 bed volumes of methanol.
  • the eluate is concentrated to dryness and taken up in 700 ml of methanol.
  • the eluate is concentrated 100:1.
  • the analysis is carried out using a 1090 HPLC unit from Hewlett Packard.
  • a microbore column 125/2 Nucleosil 120-5 C 18 ) from Machery-Nagel (Düren) is used.
  • Elution is carried out using a gradient of water/acetonitrile from initially 75:25 up to 50:50 after 5.5 minutes. This ratio is maintained up to the 7th minute, in order to then increase it up to the 10th minute to 100% acetonitrile.
  • Measurement is carried out at a wavelength of 250 nm and a bandwidth of 4 nm.
  • the diode array spectra are measured in the wavelength range from 200 to 400 nm.
  • two novel substances with R t 5.29 and R t 5.91 stand out, whose adsorption spectra are identical with those of epothilones A and B ( FIG. 1 ; E corresponds to A, F corresponds to B). These substances are only formed in traces under the given fermentation conditions.
  • a culture of Sorangium cellulosum So ce90 is used which has been shaken for four days in the presence of 2% XAD 16 adsorber resin (Rohm and Haas, Frankfurt/M.) at 30° C. and 160 rpm.
  • the culture medium has the following composition in g/litre of distilled water: potato starch (Maizena), 8; glucose (Maizena), 8; defatted soya flour, 2; yeast extract (Marcor), 2; ethylenediaminetetraacetic acid, iron(III) sodium salt, 0.008; MgSO 4 ⁇ 7H 2 O, 1; CaCl 2 ⁇ 2 H 2 O, 1; HEPES 11.5.
  • the pH is adjusted to 7.4 before autoclaving with KOH.
  • the XAD is separated from the culture by sieving through a stainless steel sieve (200 ⁇ m mesh width).
  • the bacteria are sedimented by centrifugation for 10 min at 10,000 rpm and the pellet is resuspended in 1 ⁇ 5 of the culture supernatant.
  • Epothilone A or epothilone B in methanolic solution is then added to the concentrated bacterial suspension in a concentration of 0.5 g/ litre.
  • the culture is cultured further as described above.
  • To analyse the biotransformation a 1 ml sample is taken at the desired times, 0.1 ml of XAD is added and the sample is shaken at 30° C. for 30 min.
  • the XAD is eluted with methanol.
  • FIG. 4 Kinetics of the biotransformation of epothilone A to epothilone E
  • FIG. 5 Kinetics of the biotransformation of epothilone B to epothilone F.
  • strain Sorangium cellulosum So ce90 is grown for four days in 8.5 l of the above medium (but without XAD addition) in a 10 litre bioreactor at 30° C., a speed of rotation of 150 rpm and an introduction of 1 l/min of air.
  • the culture is then concentrated to 3 l by crossflow filtration.
  • 0.6 m 2 of a membrane having a pore size of 0.3 ⁇ m are used.
  • the concentrated culture is transferred to a 4 litre bioreactor and a methanolic solution of 1 g of epothilone A in 10 ml of methanol is added.
  • the culture is then cultured further for a period of time of 21.5 h.
  • the temperature is 32° C.
  • the stirrer speed is 455 rpm and the introduction of air takes place at 6 l/min.
  • 100 ml of XAD is added and the mixture is incubated further for 1 h.
  • the XAD is separated from the cells by screening and exhaustively eluted with methanol.
  • the concentrated eluate is analysed by means of HPLC.
  • the polymerization test is an in vitro test using purified tubulin from pigs' brain. Evaluation is carried out photometrically. Polymerization-promoting substances such as the epothilones reduce the time up to which half-maximal polymerization has taken place, i.e. the shorter the time, the more active the compound. w, x, y and z are four independent experiments, the relative activity is expressed in the last column in % of the control; again the lowest values indicate the best activity. The ranking list corresponds reasonably accurately to that found in cell cultures.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to epothilones C, D, E and F, their preparation and their use for the production of therapeutic compositions and compositions for plant production.

Description

  • The present application is a divisional application, claiming priority to application Ser. No. 10/988,328, filed on Nov. 12, 2004, which is a division of application Ser. No. 09/313,524, filed on May 17, 1999, which is a continuation of application No. PCT/EP97/06442, filed on Nov. 18, 1997, which claims priority to DE 197 07 506.1, filed Feb. 25, 1997 and DE 196 47 580.5, filed Nov. 18, 1996.
  • The present invention relates to epothilones C, D, E and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.
  • Epothilones C and D
  • According to one embodiment, the invention relates to epothilones [C and D] which are obtainable in that
  • (a) Sorangium cellulosum DSM 6773 is cultured in a manner known per se in the presence of an adsorber resin,
  • (b) the adsorber resin is removed from the culture and washed with a water/methanol mixture,
  • (c) the washed adsorber resin is eluted with methanol and the eluate is concentrated to give a crude extract,
  • (d) the concentrate obtained is extracted with ethyl acetate, the extract is concentrated and partitioned between methanol and hexane,
  • (e) the methanolic phase is concentrated to give a raffinate and the concentrate is fractionated on a Sephadex column,
  • (f) a fraction containing metabolic products of the microorganism employed is obtained,
  • (g) the fraction obtained is chromatographed on a C18 reverse phase to a methanol/water mixture and, sequentially
  • after a first fraction containing epothilone A and
  • a second fraction containing epothilone B
  • a third fraction containing a first further epothilone and
  • a fourth fraction containing a second further epothilone are obtained and
  • (h1) and the epothilone of the first further fraction and/or
  • (h2) the epothilone of the second further fraction are isolated.
  • The invention further relates to an epothilone [C] of the empirical formula C26H39NO5S, characterized by the 1H- and 13C-NMR spectrum as in Table 1.
  • The invention furthermore relates to epothilone C of the formula:
    Figure US20060264482A1-20061123-C00001
    • Epothilone C R═H
  • The invention furthermore relates to epothilone [D] of the empirical formula C27H41NO5S, characterized by the 1H- and 13C-NMR spectrum as in Table 1.
  • The invention furthermore relates to epothilone D of the formula:
    Figure US20060264482A1-20061123-C00002
    • Epothilone D R═CH3
  • Epothilones C and D can be used for the preparation of the compounds of the following formula 1, where for their derivatization reference can be made to the derivatization methods described in WO-A-97/19 086.
    Figure US20060264482A1-20061123-C00003
    In the above formula 1:
    • R═H, C1-4-alkyl;
    • R1, R2, R3, R4, R5═H, C1-6-alkyl,
      • C1-6-acylbenzoyl,
      • C1-4-trialkylsilyl,
      • benzyl,
      • phenyl,
      • C1-6-alkoxy-,
      • C6-alkyl-, hydroxy- and halogen-substituted benzyl or phenyl;
        where two of the radicals R1 to R5 can also combine to form the group —(CH2)n— with n=1 to 6 and the alkyl or acyl groups contained in the radicals are straight-chain or branched radicals;
        Y and Z are either identical or different and are each hydrogen, halogen, such as F, Cl, Br or I, pseudohalogen, such as —NCO, —NCS or —N3, OH, O—(C1-6)-acyl, O—(C1-6)-alkyl, O-benzoyl. Y and Z can also be the O atom of an epoxide, epothilone A and B not being claimed, or form one of the C—C bonds of a C═C double bond.
  • Thus the 12,13-double bond can be selectively
  • hydrogenated, for example catalytically or with di-imine, a compound of the formula 1 being obtained with Y═Z═H; or
  • epoxidized, for example with dimethyldioxirane or a peracid, a compound of the formula 1 being obtained with Y and Z═—O—; or
  • converted into the dihalides, dipseudohalides or diazides, a compound of the formula 1 being obtained with Y and Z═Hal, pseudo-hal or N3.
  • Epothilones E and F
  • According to a further embodiment the invention relates to a biotransformant of epothilone A, which is obtainable in that
    • (a) Sorangium cellulosum DSM 6773 is cultured in a manner known per se in the presence of an adsorber resin, removed from the adsorber resin and, if appropriate, the total amount or a part of the separated culture is treated with a methanolic solution of epothilone A,
    • (b) the culture treated with epothilone A is incubated and then treated with adsorber resin,
    • (c) the adsorber resin is separated from the culture, eluted with methanol and the eluate is concentrated to give a crude extract,
    • (d) the crude extract is partitioned between ethyl acetate and water, the ethyl acetate phase is separated off and concentrated to give an oil,
    • (e) the oil is chromatographed on a reverse phase under the following conditions:
    •  column material: Nucleosil 100 C-18 7 μm
    •  column dimensions: 250×16 mm
    •  eluent: methanol/water=60:40
    •  flow rate: 10 ml/min
      and fractions having a content of biotransformant and which can be detected by UV extinction at 254 nm and have an Rt value of 20 min are separated off and the biotransformants are isolated.
  • The invention furthermore relates to a biotransformant of epothilone A of this type, which is obtainable in that in stage (a) a culture is separated off which is three or four or more days old.
  • The invention furthermore relates to a biotransformant of epothilone A of this type, which is obtainable in that in stage (b) incubation is carried out for one or two or more days.
  • The invention furthermore relates to a compound of the empirical formula C26H39NO7S, characterized by the following 1H-NMR spectrum (300 MHz, CDCl3): delta=2.38 (2-Ha), 2.51 (2-Hb), 4.17 (3-H), 3.19 (6-H), 3.74 (7-H), 1.30-1.70 (8-H, 9-H2, 10-H2, 11-H2), 2.89 (12-H), 3.00 (13-H), 1.88 (14-Ha), 2.07 (14-Hb), 5.40 (15-H), 6.57 (17-H), 7.08 (19-H), 4.85 (21-H2), 1.05 (22-H3), 1.32 (23-H3), 1.17 (24-H3), 0.97 (25-H3), 2.04 (27-H3)
  • The invention furthermore relates to a compound (epothilone E) of the formula:
    Figure US20060264482A1-20061123-C00004
  • Epothilone E R═H
  • According to a further embodiment, the invention relates to a biotransformant of epothilone B, which is obtainable in that
    • (a) Sorangium cellulosum DSM 6773 is cultured in a manner known per se in the presence of an adsorber resin, separated from the adsorber resin and, if appropriate, the total amount or a part of the separated culture is treated with a methanolic solution of epothilone B,
    • (b) the culture treated with epothilone B is incubated and then treated with adsorber resin,
    • (c) the adsorber resin is separated from the culture, eluted with methanol and the eluate is concentrated to give a crude extract,
    • (d) the crude extract is partitioned between ethyl acetate and water, the ethyl acetate phase is separated off and concentrated to give an oil,
    • (e) the oil is chromatographed on a reverse phase under the following conditions:
    •  column material: Nucleosil 100 C-18 7 μm
    •  column dimensions: 250×16 mm
    •  eluent: methanol/water=60:40
    •  flow rate: 10 ml/min
      and fractions having a content of biotransformant and which can be detected by UV extinction at 254 nm and have an Rt value of 24.5 min are separated off and the biotransformants are isolated.
  • The invention furthermore relates to a biotransformant of epothilone B of this type, which is obtainable in that in stage (a) a culture is separated off which is three or four or more days old.
  • The invention furthermore relates to a biotransformant of epothilone B of this type, which is obtainable in that in stage (b) incubation is carried out for one or two or more days.
  • The invention furthermore relates to a compound of the empirical formula C27H41NO7S, characterized by the following 1H-NMR spectrum (300 MHz, CDCl3): delta=2.37 (2-Ha), 2.52 (2-Hb), 4.20 (3-H), 3.27 (6-H), 3.74 (7-H), 1.30-1.70 (8-H, 9-H2, 10-H2, 11-H2), 2.78 (13-H), 1.91 (14-H), 2.06 (14-Hb), 5.42 (15-H), 6.58 (17-H), 7.10 (19-H), 4.89 (21-H2), 1.05 (22-H3), 1.26 (23-H3), 1.14 (24-H3), 0.98 (25-H3), 1.35 (26-H3), 2.06 (27-H3).
  • The invention furthermore relates to a compound (epothilone F) of the formula:
    Figure US20060264482A1-20061123-C00005
    • Epothilone F R═CH3
    BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a HPLC analysis of an XAD eluate at the end of a fermentation.
  • FIG. 2 shows an enrichment of epothilone E and F in a fermentation broth after feeding of a mixture of epothilone A and B, analysed after incubation for 48 hours.
  • FIG. 3 shows kinetics of the biotransformation of epothilone A to epothilone E by Sorangium cellulosum So ce90.
  • FIG. 4 shows biotransformation of epothilone A to epothilone E.
  • FIG. 5 shows biotransformation of epothilone B to epothilone F.
  • Preparation and Compositions
  • The compounds or epothilones according to the invention are obtainable by the abovementioned measures.
  • The invention furthermore relates to compositions for plant protection in agriculture, forestry and/or horticulture, consisting of one or more of the abovementioned epothilones C, D, E and F or consisting of one or more of the abovementioned epothilones in addition to one or more customary carrier(s) and/or diluent(s).
  • The invention finally relates to therapeutic compositions, consisting of one or more of the abovementioned compounds or one or more of the abovementioned compounds in addition to one or more customary carrier(s) and/or diluent(s). In particular, these compositions can show cytotoxic activities and/or bring about immunosuppression and/or be employed for the control of malignant tumours, it being particularly preferably possible for them to be used as cytostatics.
  • In the following, the invention is illustrated and described in greater detail by the description of some selected working examples.
    • EXAMPLES Example 1 Epothilones C and D
  • A. Production Strain and Culture Conditions According to the Epothilone Basic Patent DE-B-41 38 042.
  • B. Production with DSM 6773
  • 75 1 of culture are grown as described in the basic patent and used for the inoculation of a production fermenter with 700 1 of production medium consisting of 0.8% starch, 0.2% glucose, 0.2% soya flour, 0.2% yeast extract, 0.1% CaCl2×2H2O, 0.1% MgSO4×7H2O, 8 mg/l of Fe-EDTA, pH=7.4 and optionally 15 l of Amberlite XAD-16 adsorber resin. The fermentation lasts 7-10 days at 30 C, aeration with 2 m3/hr. By controlling the speed of rotation, the pO2 is kept at 30%.
  • C. Isolation
  • The adsorber resin is separated from the culture using a 0.7 m2, 100 mesh process filter and freed from polar concomitants by washing with 3 bed volumes of water/methanol 2:1. By elution with 4 bed volumes of methanol, a crude extract is obtained which is evaporated in vacuo until the water phase appears. This is extracted three times with the same volume of ethyl acetate. Evaporation of the organic phase affords 240 g of crude extract, which is partitioned between methanol and heptane in order to separate off lipophilic concomitants. By evaporation in vacuo, 180 g of raffinate are obtained from the methanol phase and are fractionated into three portions on Sephadex LH-20 (column 20×100 cm, 20 ml/min of methanol). The epothilones are contained in the fraction of a total of 72 g eluted with a 240-300 min retention time. To separate the epothilones, the fraction is chromatographed in three portions on Lichrosorb RP-18 (15 μm, column 10×40 cm, eluent 180 ml/min methanol/water 65:35). After epothilone A and B, epothilone C, with Rt=90-95 min, and epothilone D, 100-110 min, are eluted and after evaporation in vacuo obtained in a yield of 0.3 g each as colourless oils.
    D. Physical Properties
    Figure US20060264482A1-20061123-C00006
    • Epothilone C R═H
    • Epothilone D R═CH3
      Epothilone C
    • C26H39NO5S [477]
    • ESI-MS: (positive ions): 478.5 for [M+H]+
    • 1H and 13C see NMR table
    • TLC: Rf=0.82
    • TLC aluminum foil 60 F 254 Merck, eluent: dichloromethane/methanol=9:1
    • Detection: UV extinction at 254 nm. Spraying with vanillin-sulphuric acid reagent, blue-grey coloration on heating to 120° C.
    • HPLC: Rt=11.5 min
    • Column: Nucleosil 100 C-18 7 μm, 125×4 mm
    • Eluent: methanol/water=65:35
    • Flow rate: 1 ml/min
    • Detection: diode array
      Epothilone D
    • C27H41NO5S [491]
    • ESI-MS: (positive ions): 492.5 for [M+H]+
    • 1H and 13C see NMR table
    • TLC: Rf=0.82
    • TLC aluminum foil 60 F 254 Merck, eluent: dichloromethane/methanol=9:1
    • Detection: UV extinction at 254 nm. Spraying with vanillin-sulphuric acid reagent, blue-grey coloration on heating to 120° C.
    • HPLC: Rt=15.3 min
    • Column: Nucleosil 100 C-18 7 μm, 125×4 mm
    • Eluent: methanol/water=65:35
    • Flow rate: 1 ml/min
  • Detection: diode array
    TABLE 1
    1H- and 13C-NMR data of epothilone C and
    epothilone D in [D6] DMSO at 300 MHz
    Epothilone C Epothilone D
    H atom δ (ppm) C atom δ (ppm) δ (ppm) C atom δ (ppm)
    1 170.3 1 170.1
    2-Ha 2.38 2 38.4 2.35 2 39.0
    2-Hb 2.50 3 71.2 2.38 3 70.8
    3-H 3.97 4 53.1 4.10 4 53.2
    3-OH 5.12 5 217.1 5.08 5 217.4
    6-H 3.07 6 45.4 3.11 6 44.4
    7-H 3.49 7 75.9 3.48 7 75.5
    7-OH 4.46 8 35.4 4.46 8 36.3
    8-H 1.34 9 27.6 1.29 9 29.9
    9-Ha 1.15 10 30.0 1.14 10 25.9
    9-Hb 1.40 11 27.6 1.38 11 31.8*
    10-Ha 1.15* 12 124.6 1.14* 12 138.3
    10-Hb 1.35* 13 133.1 1.35* 13 120.3
    11-Ha 1.90 14 31.1 1.75 14 31.6*
    11-Hb 2.18 15 76.3 2.10 15 76.6
    12-H 5.38** 16 137.3 16 137.2
    13-H 5.44** 17 119.1 5.08 17 119.2
    14-Ha 2.35 18 152.1 2.30 18 152.1
    14-Hb 2.70 19 117.7 2.65 19 117.7
    15-H 5.27 20 164.2 5.29 20 164.3
    17-H 6.50 21 18.8 6.51 21 18.9
    19-H 7.35 22 20.8 7.35 22 19.7
    21-H3 2.65 23 22.6 2.65 23 22.5
    22-H3 0.94 24 16.7 0.90 24 16.4
    23-H3 1.21 25 18.4 1.19 25 18.4
    24-H3 1.06 27 14.2 1.07 26 22.9
    25-H3 0.90 0.91 27 14.1
    26-H3 1.63
    27-H3 2.10 2.11

    *, **assignment interchangeable
    • Example 2 Epothilone A and 12,13-bisepi-epothilone A from Epothilone C
  • 50 mg of epothilone A are dissolved in 1.5 ml of acetone and treated with 1.5 ml of a 0.07 molar solution of dimethyldioxirane in acetone. After standing at room temperature for 6 hours, the mixture is evaporated in vacuo and the residue is separated by preparative HPLC on silica gel (eluent: methyl tert-butyl ether/petroleum ether/methanol 33:66:1).
  • Yield:
    • 25 mg of epothilone A, Rt=3.5 min (analyt. HPLC, 7 μm, column 4×250 mm, eluent see above, flow rate 1.5 ml/min)
      and
    • 20 mg of 12,13-bisepi-epothilone A, Rt=3.7 min, ESI-MS (pos. ions) m/e=494 [M+H]+
  • 1H-NMR in [D4] methanol, selected signals: delta=4.32 (3-H), 3.79 (7-H), 3.06 (12-H), 3.16 (13-H), 5.54 (15-H), 6.69 (17-H), 1.20 (22-H), 1.45 (23-H).
    Figure US20060264482A1-20061123-C00007
    • 12,13-bisepi-epothilone A R═H
    Example 3 Epothilone E and F, Novel Biotransformation Products of Epothilones A and B
  • Production Strain:
  • The production strain Sorangium cellulosum So ce90 was isolated in July 1985 in GBF from a soil sample from the banks of the Zambesi and deposited on 28.10.91 in the German Collection for Microorganisms under No. DSM 6773.
  • The characterization of the producer and the culture conditions are described in:
  • Höfle, G.; N. Bedorf, K. Gerth & H. Reichenbach: Epothilones, processes for their preparation and compositions containing them. DE 41 38 042 A1, laid open on 27 May 1993.
  • Formation of Epothilones E and F During Fermentation:
  • A typical fermentation proceeds in the following manner: A 100 l bioreactor is filled with 60 l of medium (0.8% starch; 0.2% glucose; 0.2% soya flour; 0.2% yeast extract; 0.1% CaCl2×2H2O; 0.1% MgSO4×7H2O; 8 mg/l of Fe-EDTA; pH 7.4). 2% of adsorber resin (XAD-16, Rohm & Haas) are additionally added. The medium is sterilized by autoclaving (2 hours, 120° C.). Inoculation is carried out with 10 l of a preculture grown in the same medium (additionally 50 mM HEPES buffer pH 7.4) in a shaker flask (160 rpm, 30° C.). Fermentation is carried out at 32° C. with a stirrer speed of 500 rpm and an introduction of 0.2 N1 per m3 per hour of air, the pH is kept at 7.4 by addition of KOH. The fermentation lasts 7 to 10 days. The epothilones formed are continuously bound to the adsorber resin during the fermentation. After separating off the culture broth (e.g. by screening in a process filter), the resin is washed with 3 bed volumes of water and eluted with 4 bed volumes of methanol. The eluate is concentrated to dryness and taken up in 700 ml of methanol.
  • HPLC Analysis of the XAD Eluate:
  • In relation to the starting volume of the reactor (70 l), the eluate is concentrated 100:1. The analysis is carried out using a 1090 HPLC unit from Hewlett Packard. To separate the constituents, a microbore column (125/2 Nucleosil 120-5 C18) from Machery-Nagel (Düren) is used. Elution is carried out using a gradient of water/acetonitrile from initially 75:25 up to 50:50 after 5.5 minutes. This ratio is maintained up to the 7th minute, in order to then increase it up to the 10th minute to 100% acetonitrile.
  • Measurement is carried out at a wavelength of 250 nm and a bandwidth of 4 nm. The diode array spectra are measured in the wavelength range from 200 to 400 nm. In the XAD eluate, two novel substances with Rt 5.29 and Rt 5.91 stand out, whose adsorption spectra are identical with those of epothilones A and B (FIG. 1; E corresponds to A, F corresponds to B). These substances are only formed in traces under the given fermentation conditions.
  • Biotransformation of Epothilone A and B to Epothilone E and F:
  • A 500 ml culture of So ce90, 4 days old and maintained with adsorber resin, is used for the specific biotransformation. 250 ml of this are transferred to a sterile 1 l Erlenmeyer flask leaving behind the XAD. A methanolic solution of a mixture of a total of 36 mg of epothilone A+14 mg of B is then added and the flask is incubated on a shaking rack for two days at 30° C. and 200 rpm. The formation of the epothilones E and F is analysed directly from 10 μl of the centrifuged culture supernatant (FIG. 2). The conversion takes place only in the presence of the cells and is dependent on the cell densities employed and the time. Kinetics of the conversion are shown for epothilone A in FIG. 3.
  • Isolation of Epothilone E and F
  • To isolate epothilone E and F, three shaker flask batches from the biotransformation (see above) are combined and shaken with 20 ml of XAD-16 for 1 h. The XAD is obtained by screening and eluted with 200 ml of methanol. The eluate is evaporated in vacuo to give 1.7 g of crude extract. This is partitioned between 30 ml of ethyl acetate and 100 ml of water. On evaporation in vacuo, 330 mg of an oily residue are obtained from the ethyl acetate phase, which are chromatographed in five runs on a 250×20 mm RP-18 column (eluent: methanol/water 58:42, detection 254 nm).
  • Yield: epothilone E 50 mg
      • F 10 mg
        Biological Action of Epothilone E:
  • In cell cultures, the concentration was determined which reduces the growth by 50% (IC50) and compared with the values for epothilone A.
    IC50 (ng/ml)
    Cell line Epothilone E Epothilone A
    HeLa.KB-3.1 (human) 5 1
    Mouse fibroblasts, L929 20 4

    Epothilone E
    • C26H39HO7S [509]
    • ESI-MS: (positive ions): 510.3 for [M+H]+
    • TLC: Rf=0.58
    • TLC aluminum foil 60 F 254 Merck, eluent: dichloromethane/methanol=9:1
    • Detection: UV extinction at 254 nm. Spraying with vanillin-sulphuric acid reagent, blue-grey colouration on heating to 120° C.
    • HPLC: Rt=5.0 min
    • Column: Nucleosil 100 C-18 7 μm, 250×4 mm
    • Eluent: methanol/water=60:40
    • Flow rate: 1.2 ml/min
    • Detection: diode array
      1H-NMR (300 MHz, CDCl3): delta=2.38 (2-Ha), 2.51 (2-Hb), 4.17 (3-H), 3.19 (6-H), 3.74 (7-H), 1.30-1.70 (8-H, 9-H2, 10-H2, 11-H2), 2.89 (12-H), 3.00 (13-H), 1.88 (14-Ha), 2.07 (14-Hb), 5.40 (15-H), 6.57 (17-H), 7.08 (19-H), 4.85 (21-H2), 1.05 (22-H3), 1.32 (23-H3), 1.17 (24-H3), 0.97 (25-H3), 2.04 (27-H3)
      Epothilone F
    • C27H41NO7S [523]
    • ESI-MS: (positive ions): 524.5 for [M+H]+
    • TLC: Rf=0.58
    • TLC aluminum foil 60 F 254 Merck, eluent: dichloromethane/methanol=9:1
    • Detection: UV extinction at 254 nm. Spraying with vanillin-sulphuric acid reagent, blue-grey colouration on heating to 120° C.
    • HPLC: Rt=5.4 min
    • Column: Nucleosil 100 C-18 7 μm, 250×4 mm
    • Eluent: methanol/water=60:40
    • Flow rate: 1.2 ml/min
    • Detection: diode array
      1H-NMR (300 MHz, CDCl3): delta=2.37 (2-Ha), 2.52 (2-Hb), 4.20 (3-H), 3.27 (6-H), 3.74 (7-H), 1.30-1.70 (8-H, 9-H2, 10-H2, 11-H2), 2.78 (13-H), 1.91 (14-H), 2.06 (14-Hb), 5.42 (15-H), 6.58 (17-H), 7.10 (19-H), 4.89 (21-H2), 1.05 (22-H3), 1.26 (23-H3), 1.14 (24-H3), 0.98 (25-H3), 1.35 (26-H3), 2.06 (27-H3).
    Example 4 Preparation of Epothilone E and F by Biotransformation with Sorangium cellulosum So ce90
  • 1) Carrying out the Biotransformation:
  • For the biotransformation, a culture of Sorangium cellulosum So ce90 is used which has been shaken for four days in the presence of 2% XAD 16 adsorber resin (Rohm and Haas, Frankfurt/M.) at 30° C. and 160 rpm. The culture medium has the following composition in g/litre of distilled water: potato starch (Maizena), 8; glucose (Maizena), 8; defatted soya flour, 2; yeast extract (Marcor), 2; ethylenediaminetetraacetic acid, iron(III) sodium salt, 0.008; MgSO4×7H2O, 1; CaCl2×2 H2O, 1; HEPES 11.5. The pH is adjusted to 7.4 before autoclaving with KOH. The XAD is separated from the culture by sieving through a stainless steel sieve (200 μm mesh width). The bacteria are sedimented by centrifugation for 10 min at 10,000 rpm and the pellet is resuspended in ⅕ of the culture supernatant. Epothilone A or epothilone B in methanolic solution is then added to the concentrated bacterial suspension in a concentration of 0.5 g/ litre. The culture is cultured further as described above. To analyse the biotransformation, a 1 ml sample is taken at the desired times, 0.1 ml of XAD is added and the sample is shaken at 30° C. for 30 min. The XAD is eluted with methanol. The eluate is concentrated to dryness and taken up again in 0.2 ml of methanol. This sample is analysed by means of HPLC. FIG. 4) Kinetics of the biotransformation of epothilone A to epothilone E FIG. 5) Kinetics of the biotransformation of epothilone B to epothilone F.
  • 2) Preparation of Epothilone E by Biotransformation of 1 g of Epothilone A.
  • The strain Sorangium cellulosum So ce90 is grown for four days in 8.5 l of the above medium (but without XAD addition) in a 10 litre bioreactor at 30° C., a speed of rotation of 150 rpm and an introduction of 1 l/min of air.
  • The culture is then concentrated to 3 l by crossflow filtration. For this purpose, 0.6 m2 of a membrane having a pore size of 0.3 μm are used.
  • The concentrated culture is transferred to a 4 litre bioreactor and a methanolic solution of 1 g of epothilone A in 10 ml of methanol is added. The culture is then cultured further for a period of time of 21.5 h. The temperature is 32° C., the stirrer speed is 455 rpm and the introduction of air takes place at 6 l/min. At the time of harvesting, 100 ml of XAD is added and the mixture is incubated further for 1 h. The XAD is separated from the cells by screening and exhaustively eluted with methanol. The concentrated eluate is analysed by means of HPLC.
  • Balancing of the Biotransformation:
    • Epothilone A employed: 1000 mg=100%
    • Epothilone A recovered after 21.5 h: 53.7 mg=5.4%
    • Epothilone E formed after 21.5 h: 661.4 mg=66.1%
    • Epothilone A completely decomposed:=28.5%
    Experiment 5
  • The epothilones according to the invention were tested with cell cultures (Table 2) and for promotion of polymerization (Table 3).
    TABLE 2
    Epothilone tests with cell cultures
    Epothilone
    B C
    A 507 477 D E F
    493 IC-50 [ng/ml] 491 509 523
    Mouse fibroblasts L 4 1 100 20 20 1.5
    929
    human tumor cell lines:
    HL-60 (leukaemia) 0.2 0.2 10 3 1 0.3
    K-562 (leukaemia) 0.3 0.3 20 10 2 0.5
    U-937 (lymphoma) 0.2 0.2 10 3 1 0.2
    KB-3.1 (carcinoma 1 0.6 20 12 5 0.5
    of the cervix)
    KB-V1 (carcinoma 0.3 0.3 15 3 5 0.6
    of the cervix multires)
    A-498 (carcinoma — 1.5 150 20 20 3
    of the kidney)
    A-549 (carcinoma 0.7 0.1 30 10 3 0.1
    of the lung)
  • TABLE 3
    Polymerization test with epothilones
    Parameter: Time up to the half-maximal polymerization of the control
    Agent Agent
    Measurement: w x y z [s] [%]
    Control 200 170 180 210 190 100
    Epothilone A 95 60 70 70 74 39
    Epothilone B 23 25 30 26 14
    Epothilone C 125 76 95 80 94 49
    Epothilone D 125 73 120 106 56
    Epothilone E 80 60 50 45 59 31
    Epothilone F 80 40 30 50 50 26

    Standard Test with 0.9 mg of Tubulin/ml and 1 μM Sample Concentration
  • The polymerization test is an in vitro test using purified tubulin from pigs' brain. Evaluation is carried out photometrically. Polymerization-promoting substances such as the epothilones reduce the time up to which half-maximal polymerization has taken place, i.e. the shorter the time, the more active the compound. w, x, y and z are four independent experiments, the relative activity is expressed in the last column in % of the control; again the lowest values indicate the best activity. The ranking list corresponds reasonably accurately to that found in cell cultures.

Claims (4)

1-16. (canceled)
17. A compound of the formula:
Figure US20060264482A1-20061123-C00008
said compound having a state of purity such as to be substantially free of other major metabolic products produced by Sorangium cellulosum.
18. A composition comprising at least one compound according to claim 1 and at least one carrier or diluent.
19. A method of treating malignant tumors comprising administering to a recipient in need thereof a therapeutic amount of a compound of the formula
Figure US20060264482A1-20061123-C00009
US11/412,536 1996-11-18 2006-04-27 Epothilones C, D, E and F, preparation and compositions Abandoned US20060264482A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/412,536 US20060264482A1 (en) 1996-11-18 2006-04-27 Epothilones C, D, E and F, preparation and compositions
US12/110,781 US20080293784A1 (en) 1996-11-18 2008-04-28 Epothilones c, d, e and f, preparation and compositions
US12/434,078 US7759375B2 (en) 1996-11-18 2009-05-01 Epothilones C, D, E, and F, preparation and compositions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE19647580.5 1996-11-18
DE19647580 1996-11-18
DE19707506.1 1997-02-25
DE19707506 1997-02-25
PCT/EP1997/006442 WO1998022461A1 (en) 1996-11-18 1997-11-18 Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US31352499A 1999-05-17 1999-05-17
US10/988,328 US7067544B2 (en) 1996-11-18 2004-11-12 Epothilones C, D, E and F, preparation and compositions
US11/412,536 US20060264482A1 (en) 1996-11-18 2006-04-27 Epothilones C, D, E and F, preparation and compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/988,328 Division US7067544B2 (en) 1996-11-18 2004-11-12 Epothilones C, D, E and F, preparation and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/110,781 Continuation US20080293784A1 (en) 1996-11-18 2008-04-28 Epothilones c, d, e and f, preparation and compositions

Publications (1)

Publication Number Publication Date
US20060264482A1 true US20060264482A1 (en) 2006-11-23

Family

ID=26031383

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/988,328 Expired - Fee Related US7067544B2 (en) 1996-11-18 2004-11-12 Epothilones C, D, E and F, preparation and compositions
US11/412,536 Abandoned US20060264482A1 (en) 1996-11-18 2006-04-27 Epothilones C, D, E and F, preparation and compositions
US12/110,781 Abandoned US20080293784A1 (en) 1996-11-18 2008-04-28 Epothilones c, d, e and f, preparation and compositions
US12/409,823 Expired - Fee Related US7846952B2 (en) 1996-11-18 2009-03-24 Epothilones C, D, E, and F, preparation and compositions
US12/434,078 Expired - Fee Related US7759375B2 (en) 1996-11-18 2009-05-01 Epothilones C, D, E, and F, preparation and compositions
US12/961,447 Expired - Fee Related US8076490B2 (en) 1996-11-18 2010-12-06 Epothilones C, D, E, and F, preparation and compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/988,328 Expired - Fee Related US7067544B2 (en) 1996-11-18 2004-11-12 Epothilones C, D, E and F, preparation and compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/110,781 Abandoned US20080293784A1 (en) 1996-11-18 2008-04-28 Epothilones c, d, e and f, preparation and compositions
US12/409,823 Expired - Fee Related US7846952B2 (en) 1996-11-18 2009-03-24 Epothilones C, D, E, and F, preparation and compositions
US12/434,078 Expired - Fee Related US7759375B2 (en) 1996-11-18 2009-05-01 Epothilones C, D, E, and F, preparation and compositions
US12/961,447 Expired - Fee Related US8076490B2 (en) 1996-11-18 2010-12-06 Epothilones C, D, E, and F, preparation and compositions

Country Status (24)

Country Link
US (6) US7067544B2 (en)
EP (2) EP0941227B2 (en)
JP (1) JP4274583B2 (en)
KR (1) KR100538095B1 (en)
CN (2) CN100344627C (en)
AT (2) ATE267197T1 (en)
AU (1) AU753546B2 (en)
BR (1) BR9713363B1 (en)
CA (1) CA2269118C (en)
CY (1) CY2542B1 (en)
CZ (2) CZ303422B6 (en)
DE (2) DE59711647D1 (en)
DK (2) DK1367057T3 (en)
ES (2) ES2312695T3 (en)
HK (2) HK1022314A1 (en)
HU (1) HU229833B1 (en)
IL (1) IL129558A (en)
NO (1) NO319984B1 (en)
NZ (1) NZ335383A (en)
PL (1) PL193229B1 (en)
PT (2) PT1367057E (en)
RU (1) RU2198173C2 (en)
TW (1) TW408119B (en)
WO (1) WO1998022461A1 (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT903348E (en) 1995-11-17 2002-11-29 Biotechnolog Forschung Mbh Gbf EPOTILONE DERIVATIVES AND THEIR PREPARATION
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
CA2269118C (en) 1996-11-18 2012-05-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
DE19826988A1 (en) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
NZ508326A (en) * 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19846493A1 (en) * 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
EP1140928A4 (en) * 1998-12-23 2002-10-02 Bristol Myers Squibb Co Microbial transformation method for the preparation of an epothilone
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
BR0008379A (en) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
BR0009721A (en) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
NZ546497A (en) * 2000-04-28 2008-04-30 Kosan Biosciences Inc Production of polyketides
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
SK288098B6 (en) 2001-01-25 2013-07-02 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
EE200300397A (en) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
EP1364040B1 (en) 2001-02-27 2006-05-03 Gesellschaft für biotechnologische Forschung mbH (GBF) Degradation of epothilones and ethynyl substituted epothilones
DK1385522T3 (en) 2001-02-27 2009-10-12 Novartis Ag Combination containing a signal transduction inhibitor and an epothilone derivative
KR20040025904A (en) 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2449077A1 (en) 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
IL162595A0 (en) 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1483251T1 (en) 2002-03-12 2010-03-31 Bristol Myers Squibb Co C3-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7507564B2 (en) * 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
CN102532120A (en) * 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 Synthesis of EPOTHILONE, intermediates thereto, analogues and uses thereof
JP4523843B2 (en) 2002-09-23 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー Method for producing, isolating and purifying epothilone B and X-ray crystal structure of epothilone B
JP4672368B2 (en) * 2002-10-15 2011-04-20 ボード・オブ・スーパーバイザーズ・オブ・ルイジアナ・ステイト・ユニバーシティ・アンド・アグリカルチュラル・アンド・メカニカル・カレッジ Use of epothilone derivatives for the treatment of hyperparathyroidism
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
CN100359014C (en) * 2003-01-28 2008-01-02 北京华昊中天生物技术有限公司 Novel epothilones compound and its preparation method and application
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
RU2425838C2 (en) 2004-04-07 2011-08-10 Новартис Аг Iap inhibitors
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
PT1817013E (en) * 2004-11-18 2008-08-07 Brystol Myers Squibb Company Enteric coated bead comprising ixabepilone
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GT200600430A (en) 2005-09-27 2007-05-21 CARBOXYAMINE COMPOUNDS AND SAME USE METHODS
WO2007057457A2 (en) 2005-11-21 2007-05-24 Novartis Ag Neuroendocrine tumor treatment using mtor inhibitors
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20090233905A1 (en) 2006-04-05 2009-09-17 Gregory Peter Burke Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
MX2008012715A (en) 2006-04-05 2008-10-14 Novartis Ag Combinations of therapeutic agents for treating cancer.
MX2008014292A (en) 2006-05-09 2008-11-18 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof.
MX2009003185A (en) 2006-09-29 2009-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors.
MX2009005849A (en) 2006-12-04 2009-08-12 Univ Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna.
CA2677803A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
EP2359818A1 (en) 2007-02-15 2011-08-24 Novartis AG Combination of LBH589 with HSP 90 inhibitors for treating cancer
BRPI0908603A2 (en) 2008-03-24 2020-08-18 Novartis Ag matrix metalloprotease inhibitors based on arylsulfonamide.
MX2010010502A (en) 2008-03-26 2010-10-26 Novartis Ag Hydroxamate-based inhibitors of deacetylases b.
CN101362784A (en) * 2008-10-06 2009-02-11 山东大学 Ebomycin glycosides compounds, composition using the same as activity component and use thereof
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
PL2391366T3 (en) 2009-01-29 2013-04-30 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
JP5456891B2 (en) 2009-06-26 2014-04-02 ノバルティス アーゲー 1,3-disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en) 2009-08-12 2016-05-17 Novartis Ag Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
EA201200318A1 (en) 2009-08-20 2012-09-28 Новартис Аг Heterocyclic oximes
EP2470502A1 (en) 2009-08-26 2012-07-04 Novartis AG Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
PE20121471A1 (en) 2009-11-04 2012-11-01 Novartis Ag HELPFUL HETEROCYCLIC SULFONAMIDE DERIVATIVES AS MEK INHIBITORS
BR112012013735A2 (en) 2009-12-08 2019-09-24 Novartis Ag heterocyclic sulfonamide derivatives
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MX2012013100A (en) 2010-05-18 2013-01-22 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases.
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
CA2824521C (en) 2011-01-20 2016-06-28 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and related methods
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
ES2656218T3 (en) 2011-04-28 2018-02-26 Novartis Ag 17 alpha-hydroxylase / C17,20-lyase inhibitors
JP2014517004A (en) 2011-06-09 2014-07-17 ノバルティス アーゲー Heterocyclic sulfonamide derivatives
MX368966B (en) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Protein-polymer-drug conjugates.
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CN102863474A (en) 2011-07-09 2013-01-09 陈小平 Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN102993239A (en) 2011-09-19 2013-03-27 陈小平 Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
BR112014015442A8 (en) 2011-12-23 2017-07-04 Novartis Ag compounds and compositions for inhibiting bcl2 interaction with binding partners
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
MX2014007729A (en) 2011-12-23 2015-01-12 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners.
CN104125953A (en) 2011-12-23 2014-10-29 诺华股份有限公司 Compounds for inhibiting interaction of bcl2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
KR101372563B1 (en) * 2011-12-26 2014-03-14 주식회사 삼양바이오팜 Method of isolating and purifying epothilone A and B from epothilone containing material
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
WO2013171640A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
NZ701626A (en) 2012-05-15 2016-02-26 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP6080947B2 (en) 2012-05-15 2017-02-15 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EA201492007A1 (en) 2012-05-15 2015-03-31 Новартис Аг DERIVATIVES OF BENZAMIDE FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY
CN104321325B (en) 2012-05-24 2016-11-16 诺华股份有限公司 Pyrrolopyrrole alkanone compound
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
LT2903968T (en) 2012-10-02 2017-02-27 Gilead Sciences, Inc. Inhibitors of histone demethylases
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
JO3464B1 (en) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd Compositions of Tiacumicin Compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
CN105263906B (en) 2013-02-27 2018-11-23 吉利德科学公司 The inhibitor of histone demethylase
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
TN2015000543A1 (en) 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
MY176421A (en) 2013-09-22 2020-08-07 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
EP3054992B1 (en) 2013-10-11 2019-08-14 Asana BioSciences, LLC Protein-polymer-drug conjugates
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6517319B2 (en) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Substituted heteroaryl compounds and methods of use
AU2015241022A1 (en) 2014-03-31 2016-10-27 Gilead Sciences, Inc. Inhibitors of histone demethylases
KR20160132496A (en) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. Supramolecular combinatorial therapeutics
MX2017002451A (en) 2014-08-27 2017-05-23 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases.
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
TW201905037A (en) 2017-06-22 2019-02-01 美商梅爾莎納醫療公司 Drug-carrying polymer scaffold and method for producing protein polymer drug conjugate
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3788032B1 (en) 2018-05-04 2024-01-24 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20230021500A1 (en) 2018-10-29 2023-01-26 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (en) 2018-10-31 2021-01-29 Bio Even FLAVINE ADENINE DINUCLEOTIDE (FAD) FOR USE FOR THE PREVENTION AND / OR TREATMENT OF CANCER
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for high click release speed and yield
IL289093B1 (en) 2019-06-17 2024-10-01 Tagworks Pharmaceuticals B V Compounds for fast and efficient click release
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
KR20240105469A (en) 2021-11-25 2024-07-05 베락사 바이오테크 게엠베하 Improved antibody-payload conjugates (APC) prepared by site-specific conjugation using genetic code expansion
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
CN118574641A (en) 2021-12-08 2024-08-30 欧洲分子生物学实验室 Hydrophilic tetrazine functionalized supports for preparing targeted conjugates
EP4372000A3 (en) 2022-02-15 2024-07-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en) 2023-03-10 2024-09-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6252094B1 (en) * 1994-01-11 2001-06-26 The Scripps Research Institute Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6359140B1 (en) * 1997-02-25 2002-03-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Epothilones with modified side chain
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6410301B1 (en) * 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6537988B2 (en) * 2000-03-27 2003-03-25 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6624310B1 (en) * 1998-06-18 2003-09-23 Gesellschaft Fuer Biotechnologische Forschung, Mbh (Gbf) Epothilone minor constituents
US20030187039A1 (en) * 2002-02-15 2003-10-02 Denis Favreau Method of preparation of 21-amino epothilone derivatives
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6730803B2 (en) * 2001-09-28 2004-05-04 Sumika Fine Chemicals Co., Ltd. Synthetic intermediate for epothilone derivative and production method thereof
US20040132146A1 (en) * 2002-09-23 2004-07-08 Daniel Benigni Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6884608B2 (en) * 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7067544B2 (en) * 1996-11-18 2006-06-27 Geselllschaft Fuer Biotechnologishce Forschung Mbh (Gbf) Epothilones C, D, E and F, preparation and compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358606A3 (en) 1988-09-09 1990-10-31 Gesellschaft für Biotechnologische Forschung mbH (GBF) Microbiological method for the preparation of agrochemically useful macrocyclic lactone derivatives with a microbicidal activity
GB8909737D0 (en) * 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (en) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
JPH09502698A (en) * 1993-03-05 1997-03-18 ヘクサル・アクチエンゲゼルシャフト Ranitidine hydrochloride crystalline cyclodextrin complex, process for its production and pharmaceutical composition containing the complex
DE19639456A1 (en) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh New epothilone derivatives
DE19542986A1 (en) * 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh New epothilone derivatives useful as cytostatics
DE19645362A1 (en) 1996-10-28 1998-04-30 Ciba Geigy Ag Production of epothilone compounds with taxol-like activity
DE19636343C1 (en) 1996-08-30 1997-10-23 Schering Ag New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (en) 1996-08-30 1998-04-30 Ciba Geigy Ag Production of epothilone compounds with taxol-like activity
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE19701758A1 (en) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr New beta-keto-alcohol derivatives
US5828449A (en) 1997-02-26 1998-10-27 Acuity Imaging, Llc Ring illumination reflective elements on a generally planar surface
DE19713970B4 (en) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone Synthesis Building Blocks II - Prenyl Derivatives
WO1998047891A1 (en) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (en) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Preparation of epothilone derivatives
DE19720312A1 (en) 1997-05-15 1998-11-19 Hoechst Ag Preparation with increased in vivo tolerance
DE19726627A1 (en) 1997-06-17 1998-12-24 Schering Ag New intermediates for epothilone
DE59805727D1 (en) 1997-07-16 2002-10-31 Schering Ag THIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE
ATE368036T1 (en) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag NEW EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
KR20060002022A (en) 1998-02-05 2006-01-06 노파르티스 아게 Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
JP2002533346A (en) 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト Epothilone derivatives and their use as antitumor agents
CA2361278A1 (en) 1999-02-18 2000-08-24 Ulrich Klar 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (en) 1999-04-30 2001-02-15 Schering Ag 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252094B1 (en) * 1994-01-11 2001-06-26 The Scripps Research Institute Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US20040087634A1 (en) * 1995-11-17 2004-05-06 Gerhard Hoefle Epothilons C and D, preparation and compositions
US6613912B2 (en) * 1995-11-17 2003-09-02 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US7067544B2 (en) * 1996-11-18 2006-06-27 Geselllschaft Fuer Biotechnologishce Forschung Mbh (Gbf) Epothilones C, D, E and F, preparation and compositions
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US20040127432A1 (en) * 1996-12-13 2004-07-01 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6359140B1 (en) * 1997-02-25 2002-03-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Epothilones with modified side chain
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7235669B2 (en) * 1998-06-18 2007-06-26 Helmholtz-Zentrum Fur Infektionsforschung, Gmbh Epothilone side components
US6624310B1 (en) * 1998-06-18 2003-09-23 Gesellschaft Fuer Biotechnologische Forschung, Mbh (Gbf) Epothilone minor constituents
US6531497B1 (en) * 1998-06-22 2003-03-11 The Scripps Research Institute Epothilone derivatives and their synthesis and use
US6410301B1 (en) * 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20040176429A1 (en) * 1998-12-23 2004-09-09 Wenying Li Microbial transformation method for the preparation of an epothilone
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US6537988B2 (en) * 2000-03-27 2003-03-25 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US6730803B2 (en) * 2001-09-28 2004-05-04 Sumika Fine Chemicals Co., Ltd. Synthetic intermediate for epothilone derivative and production method thereof
US6884608B2 (en) * 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
US20030187039A1 (en) * 2002-02-15 2003-10-02 Denis Favreau Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040132146A1 (en) * 2002-09-23 2004-07-08 Daniel Benigni Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B

Also Published As

Publication number Publication date
DE59711647D1 (en) 2004-06-24
PL333435A1 (en) 1999-12-06
EP0941227B9 (en) 2005-05-04
PL193229B1 (en) 2007-01-31
ES2221692T5 (en) 2009-12-14
DK0941227T3 (en) 2004-06-28
EP0941227B2 (en) 2009-10-14
AU5483798A (en) 1998-06-10
JP2001504474A (en) 2001-04-03
AU753546B2 (en) 2002-10-24
DK0941227T5 (en) 2009-10-05
EP0941227A1 (en) 1999-09-15
US20090247592A1 (en) 2009-10-01
KR20000053308A (en) 2000-08-25
CA2269118A1 (en) 1998-05-28
CN1196698C (en) 2005-04-13
IL129558A (en) 2001-10-31
EP0941227B1 (en) 2004-05-19
HU229833B1 (en) 2014-09-29
BR9713363A (en) 2000-01-25
EP1367057A1 (en) 2003-12-03
ATE267197T1 (en) 2004-06-15
JP4274583B2 (en) 2009-06-10
NZ335383A (en) 2000-10-27
IL129558A0 (en) 2000-02-29
ES2221692T4 (en) 2005-10-01
KR100538095B1 (en) 2005-12-21
US20110136185A1 (en) 2011-06-09
HUP0000497A2 (en) 2000-06-28
CZ175099A3 (en) 1999-09-15
CZ296164B6 (en) 2006-01-11
US20080293784A1 (en) 2008-11-27
WO1998022461A1 (en) 1998-05-28
EP1367057B1 (en) 2008-09-17
RU2198173C2 (en) 2003-02-10
HK1022314A1 (en) 2000-08-04
TW408119B (en) 2000-10-11
PT1367057E (en) 2008-12-04
PT941227E (en) 2004-08-31
ES2221692T3 (en) 2005-01-01
BR9713363B1 (en) 2011-02-08
ES2312695T3 (en) 2009-03-01
US7846952B2 (en) 2010-12-07
CN1680370A (en) 2005-10-12
HUP0000497A3 (en) 2001-10-29
NO992338L (en) 1999-05-14
US7759375B2 (en) 2010-07-20
ATE408612T1 (en) 2008-10-15
DK0941227T4 (en) 2008-05-19
CY2542B1 (en) 2006-06-28
US20090270466A1 (en) 2009-10-29
DK1367057T3 (en) 2009-01-19
CA2269118C (en) 2012-05-29
US20050090535A1 (en) 2005-04-28
NO319984B1 (en) 2005-10-10
US7067544B2 (en) 2006-06-27
HK1083832A1 (en) 2006-07-14
CN100344627C (en) 2007-10-24
DE59712968D1 (en) 2008-10-30
CN1237970A (en) 1999-12-08
US8076490B2 (en) 2011-12-13
NO992338D0 (en) 1999-05-14
CZ303422B6 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
US7067544B2 (en) Epothilones C, D, E and F, preparation and compositions
US6288237B1 (en) Epothilons C and D, preparation and compositions
SE503571C2 (en) Antibiotic compounds and processes for their preparation
KR960012212B1 (en) Herbicide, its preparation and use
AU613899B2 (en) Process for the preparation of a macrocyclic compound
US5021406A (en) 2-pyranone derivative and process for production thereof
EP0329361B1 (en) 2-pyranone derivatives and process for production thereof
PL163447B1 (en) Microbiological method form manufacturingmacrocyclic compounds
KR20050019892A (en) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
MXPA99004471A (en) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
JPH06293755A (en) Physiologically active aminoglycoside substance, its production and insecticidal miticide containing the substance as active component

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE